Psilocybin shows promise for rapid reduction of cancer-related depression

Psilocybin-assisted psychotherapy may provide rapid relief for cancer-related depression and anxiety, based on an analysis of clinical trial data. The review synthesizes results from randomized, placebo-controlled studies in adults with life-threatening cancer. Effects were assessed after one day and again at about two weeks, with symptoms showing faster improvements than expected from standard antidepressants. Anxiety reductions persisted at least two weeks, while antidepressant effects at the two-week point were less consistent. The analysis also suggests a higher dose (0.3 mg per kg) ranked better for reducing both depression and anxiety on the first day, with the lower dose generally performing less well. Proposed mechanisms include changes in default mode network connectivity, alongside therapeutic processes like preparation and integration. Key limitations include a small number of included trials and potential bias from psychedelic “functional unblinding,” so the findings are described as provisional and needing larger follow-up studies.